Opana Uptake Slower Than Anticipated, But Script Growth Is On The Rise
This article was originally published in The Pink Sheet Daily
Executive Summary
Scripts for Endo's oral oxymorphone reached 1,137 the week of Sept. 29, according to IMS weekly trend data.
You may also be interested in...
Endo Agrees To $90 Million In Milestone Payments For Opana ER
Firm also commits to a tiered royalty schedule to resolve dispute with development partner Penwest.
Endo Agrees To $90 Million In Milestone Payments For Opana ER
Firm also commits to a tiered royalty schedule to resolve dispute with development partner Penwest.
Endo Gains Phase II Oral Mucositis Agent With RxKinetix Acquisition
Agreement is in line with Endo’s strategy of expanding into therapeutic areas complementary to pain.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: